<DOC>
	<DOC>NCT02223117</DOC>
	<brief_summary>This "first-in-human" exploratory IND, single-center study will assess the safety, toxicity, hematology, and immunogenicity of sub-therapeutic "microdoses" of autologous Thrombosomes® in healthy human subjects.</brief_summary>
	<brief_title>Evaluation of the Safety and Immunogenicity of Autologous Thrombosomes® in Healthy Human Subjects; A Microdose Escalation Study (Cohorts 1 - 4) and Repeat Microdose Immunogenicity Study (Cohort 5)</brief_title>
	<detailed_description />
	<criteria>1. Minimum weight 110 pounds (50 kg) 2. Age 1845 years 3. Able and willing to provide informed consent 4. Has permanent address and phone/email for contact and notification, and able to come to the research site for scheduled study visits for up to 60 days after their last study infusion 5. Understands, speaks and reads standard English language 6. Normal healthy subject able to pass the universal blood donor history questionnaire and screen 1. Breastfeeding female 2. At any time, previously pregnant female 3. Participation in an experimental drug/device study within the past 30 days.</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>45 Years</maximum_age>
	<verification_date>June 2016</verification_date>
</DOC>